Although our study proved that NXK could decrease the expression of TLR2 and TLR9 proteins in TAC model mice, we did not use inhibitors of TLR2/9 or gene-editing mice to confirm the specific mechanism of NXK. The gene discussed is TLR9; the disease is persistent truncus arteriosus.